Farther Finance Advisors LLC Sells 176 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Farther Finance Advisors LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,325 shares of the company’s stock after selling 176 shares during the quarter. Farther Finance Advisors LLC’s holdings in Medpace were worth $440,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. R Squared Ltd purchased a new stake in shares of Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace during the 4th quarter valued at approximately $31,000. Stone House Investment Management LLC bought a new stake in shares of Medpace during the third quarter valued at approximately $33,000. Jones Financial Companies Lllp lifted its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after buying an additional 110 shares in the last quarter. Finally, Lindbrook Capital LLC boosted its position in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Up 2.2 %

Shares of NASDAQ:MEDP opened at $324.95 on Monday. The firm has a fifty day simple moving average of $340.28 and a two-hundred day simple moving average of $340.84. The stock has a market capitalization of $9.90 billion, a P/E ratio of 25.73, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.